Plasma rich in growth factors for the treatment of rapidly progressing refractory corneal melting due to erlotinib in nonsmall cell lung cancer

Гуарниери, А.; Alfonso-Bartolozzi, Belén; Ciufo, Gianfranco; Moreno-Montañés, Javier; Gil-Bazo, Ignacio

doi:10.1097/md.0000000000007000

Cited by 10 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 Furthermore, the use of regenerative therapy with plasma rich in growth factors (PRGF) can stimulate the healing process, and permit the management of inflammation in the ocular surfaces. 18 Nevertheless, such medical treatments rely on the accurate and timely diagnosis of disease. In the diagnosis of cancer, traditional histopathological examination, immunohistochemistry, and cytogenetic analysis are cumbersome and time-consuming.…”

Section: Discussionmentioning

confidence: 99%

<p>Ocular Metastasis in Elderly Lung Cancer Patients: Potential Risk Factors of CA-125, CA-153 and TPSA</p>

Zou

Shi

et al. 2020

CMAR

View full text Add to dashboard Cite

At present, little is known regarding the specific risk factors of ocular metastasis (OM) in elderly patients with lung cancer. This study aimed to find out the risk factors of ocular metastasis. Methods: A total of 1615 elderly patients with lung cancer were recruited into this retrospective study between April 2001 and July 2016. These patients were divided into two groups, namely OM and non-ocular metastasis (NOM). Student's t-tests, nonparametric rank sum tests, and Chi-square tests were applied to describe whether there were significant differences between the OM group and NOM group. We compared a range of serum biomarkers between the two groups of patients, including alkaline phosphatase, calcium, hemoglobin, alphafetoprotein, carcinoembryonic antigen, CA-125, CA-199, CA-153, CA-724, cytokeratin-19 fragment (CYFRA21-1), TPSA and neuron specific enolase (NSE). We used binary logistic regression analysis to determine the risk factors and receiver operating curve (ROC) analyses to assess the diagnostic value for OM in CRC patients. Results: The incidence of OM in elderly patients with lung cancer was 2.0%. Binary logistic regression indicated that CA-125, CA-153, and total prostate specific antigen (TPSA) were identified as independent risk factors of OM in patients with lung cancer (P<0.001, P<0.001, and P=0.003, respectively). The sensitivity and specificity of OM diagnosis were as follows: CA-125, 81.25% and 81.57%; CA-153, 68.75% and 83.78%; and TPSA, 81.25% and 90.03%, respectively. Conclusion: The serum concentrations of CA-125, CA-153, and TPSA have predictive value in the diagnosis of OM in elderly patients with lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Ocular Metastasis in Elderly Lung Cancer Patients: Potential Risk Factors of CA-125, CA-153 and TPSA</p>

Zou

Shi

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…6 In addition, Chow et al and Guarnieri et al encountered two patients with corneal melting due to erlotinib; however, cessation of EGFR inhibitor did not improved the symptoms in these cases. 7,8…”

Section: Discussionmentioning

confidence: 99%

When EGFR inhibitor meets autoimmune disease: Severe corneal complications in a patient with Sjögren syndrome after erlotinib treatment

Xiang

Zhang

2020

European Journal of Ophthalmology

View full text Add to dashboard Cite

Introduction: To report the first case of severe corneal complications in a patient with Sjögren syndrome after receiving erlotinib treatment. Case description: A 51-year-old woman with Sjögren syndrome presented with persistent corneal epithelial defects, which did not respond to conservative therapies. She had been diagnosed with lung cancer and was being treated with erlotinib, a kind of epidermal growth factor receptor (EGFR) inhibitor, for over 2 years. Cornea stromal melting and perforation were not avoided and a total of four penetrating keratoplasties were performed. Stable corneal surface was achieved after the erlotinib treatment was paused. Conclusion: This report, to the best of our knowledge, is the first description of severe ocular complications present in a patient with Sjögren syndrome after receiving the EGFR inhibitor. The underlying ocular or system diseases that were thought to be irrelevant upon receiving the EGFR inhibitors might negatively influence the tumor patients planning to take these kinds of targeted medication. Therefore, it is important to have eye examinations before and during the EGFR inhibitors treatment and supplement the relative contraindications (such as Sjögren syndrome) to EGFR inhibitor treatments as necessary.

show abstract

“…Erlotinib, utilized for metastatic pancreatic cancer and non-small-cell lung cancer treatment, has been linked to corneal side effects as the most serious ocular surface adverse effects encountered by patients. Five cases of corneal ulcers were reported in the literature; most of them required the treatment to b stopped, in conjunction with antibiotics, and, in one case, penetrating keratoplasty was deemed necessary [47][48][49][50][51].…”

Section: Epidermal Growth Factor Receptor Inhibitorsmentioning

confidence: 99%

Ocular Surface Side Effects of Novel Anticancer Drugs

Vitiello,

Lixi,

Coco

et al. 2024

Cancers

View full text Add to dashboard Cite

Surgery, anticancer drugs (chemotherapy, hormonal medicines, and targeted treatments), and/or radiation are common treatment strategies for neoplastic diseases. Anticancer drugs eliminate malignant cells through the inhibition of specific pathways that contribute to the formation and development of cancer. Given the ability of such pharmacological medications to combat cancerous cells, their role in the management of neoplastic diseases has become essential. However, these drugs may also lead to undesirable systemic and ocular adverse effects due to cyto/neuro-toxicity and inflammatory reactions. Ocular surface side effects are recognized to significantly impact patient’s quality of life and quality of vision. Blepharoconjunctivitis is known to be a common side effect caused by oxaliplatin, cyclophosphamide, cytarabine, and docetaxel, while anastrozole, methotrexate, and 5-fluorouracil can all determine dry eye disease. However, the potential processes involved in the development of these alterations are yet not fully understood, especially for novel drugs currently available for cancer treatment. This review aims at analyzing the potential ocular surface and adnexal side effects of novel anticancer medications, trying to provide a better understanding of the underlying pharmacological processes and useful insights on the choice of proper management.

show abstract

Plasma rich in growth factors for the treatment of rapidly progressing refractory corneal melting due to erlotinib in nonsmall cell lung cancer

Cited by 10 publications

References 14 publications

<p>Ocular Metastasis in Elderly Lung Cancer Patients: Potential Risk Factors of CA-125, CA-153 and TPSA</p>

<p>Ocular Metastasis in Elderly Lung Cancer Patients: Potential Risk Factors of CA-125, CA-153 and TPSA</p>

When EGFR inhibitor meets autoimmune disease: Severe corneal complications in a patient with Sjögren syndrome after erlotinib treatment

Ocular Surface Side Effects of Novel Anticancer Drugs

Contact Info

Product

Resources

About